Metabolic & Weight Management
Retatrutide
A triple-agonist metabolic signal for aggressive fat-loss research.
Last updated
Mechanism
Activates GLP-1, GIP, and glucagon pathways affecting satiety, insulin, and lipolysis.
Reported effects
What sources associate with this compound. Reported categories, not outcomes we have graded — each would need its own citation and rung.
- Aggressive fat loss
- Energy expenditure
- Satiety control
Dosing on file unverified
0.25-12 mg weekly, cycled 12–48 weeks
| Reported dose | Volume | Draw |
|---|---|---|
| Low — 0.25 mg | 0.25 mL | 25 units |
| High — 12 mg | 12 mL | 1,200 units |
What that assumes. Assumes 2 mg in 2 mL (1000 mcg/mL) drawn on a U-100 barrel — the preset on this record, not a recommendation and not the only way to mix it. Change the vial mass, the diluent or the barrel and every number in this table changes. Run your own.
Carried from a source that labels it unverified, and reproduced with that label attached. A record of what is reported, not a recommendation. No citation on this page establishes it.
Reconstitution
| Vial | Diluent | Concentration | Typical dose | Draw |
|---|---|---|---|---|
| 2 mg | 2 mL | 1000 mcg/mL | 250 mcg | 25 units |
mass ÷ diluent = concentration; dose ÷ concentration = volume; volume × the syringe factor = units on the barrel (100 for U-100, 40 for U-40). Run your own numbers.
Reported adverse effects
-
Nausea
-
Increased heart rate
Literature on file 3
-
human observational
NCT04881760: A Phase 2 Study of Once-Weekly LY3437943 Compared With Placebo in Participants Who Have Obesity or Are Overweight With Weight-Related Comorbidities graded on: a registered clinical study — “clinicaltrials.gov”
-
human RCT
Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial (New England Journal of Medicine 2023, cited 1022x) graded on: a phase 2 trial — “Phase 2 Trial”
-
human RCT
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA (The Lancet 2023, cited 380x) graded on: randomised and double-blind — “randomised, double-blind”
Identity
Classified as
- Lipolysis Stimulationmechanism
- This mechanism is the source of the most common category error on the site. A record can be well supported for lipolysis and carry nothing at all for fat loss, and the two live in different fields with different rungs on the ladder at /evidence/rubric.
- Subcutaneousroute
- This is the route the reconstitution arithmetic assumes. Mass divided by diluent volume gives concentration, dose divided by concentration gives volume, and volume in mL multiplied by 100 gives units on a U-100 barrel: 5 mg in 2 mL is 2.5 mg/mL, and 0.25 mg comes out at 0.1 mL, which is 10 units.
Also called
- Retatrutide
Notes unverified prose
Phase 2; NCT04881760
Not on file 8
8 of the 8 fields we track hold nothing on this record, and each says why. A blank field is a bug; a named absence is a finding.
- molecular weightno source on file holds this
- molecular formulano source on file holds this
- CAS registry numberthe reference database returned nothing for it
- PubChem identifierno source on file holds this
- amino-acid sequenceno source on file holds this
- SMILES stringthe reference database returned nothing for it
- InChIthe reference database returned nothing for it
- InChI keythe reference database returned nothing for it
Each field links to every other record missing the same thing. The full ledger holds 521 gaps across 136 records.